Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Nakano Atsushi; Miura, Tetsuji; Ura, Nobuyuki; Suzuki, Katsuo; Shimamoto, Kazuaki
Coronary Artery Disease: June 1997
Pathophysiology and Natural History: PDF Only


To assess the role of angiotensin II type 1 (AT1) receptor in the mechanism of limitation of infarct size by preconditioning.


Myocardial infarction was induced by 30 min coronary artery occlusion and 3 h reperfusion in the rabbit. The infarct size was determined by tetrazolium staining and expressed as a percentage of the area at risk (%ISAR). Rabbits were subjected to one of the following four treatments: no drug (i.e. control); administration of 1 mg/kg CV-11 974, a specific AT1 receptor antagonist, 20 min before ischemia; preconditioning with 5 min ischemia and then 5 min reperfusion; and administration of CV-11 974 plus preconditioning.


It was confirmed that the same dose of CV-11 974 (i.e. 1 mg/kg) could block the pressor response to injection of 0.5 μg/kg angiotensin II completely for 60 min. The %ISAR for the untreated control group was 45.1 ± 3.9%, and administration of CV-11 974 alone did not modify the %ISAR (47.5 ± 5.9%). The %ISAR for the group administered both CV-11 974 and subjected to preconditioning (30.4 ± 3.5%) was modestly smaller than that for the controls, but was significantly larger than for the preconditioned group (12.0 ± 1.8%). The angiotensin II level in arterial plasma did not differ before and after the 5 min preconditioning. It was shown with separate groups of rabbits that a modest protection conferred by preconditioning with 3 min ischemia was also attenuated by administration of CV-11 974 (%ISAR 28.4 ± 4.3 with CV-11 974 versus 19.3 ± 1.7% without CV-11 974, P<0.05).


These results suggest that activation of AT1 receptors by angiotensin II produced locally in the heart contributes to the limitation of infarct size by preconditioning.

© Lippincott-Raven Publishers.